Miles White

Latest Headlines

Latest Headlines

Big Mylan shareholder Abbott backs Mylan's Perrigo buy

Mylan can breathe a little easier knowing it has support from its largest shareholder in its quest to pick up Perrigo. After all, it's not just a big buyout at stake--but the opportunity to thwart its own unwanted takeover by generics rival Teva.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 2)

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

Post-pharma Abbott soars on Dx, struggles with devices

The new Abbott Laboratories is counting on med tech for revenue growth in a proprietary-drug-free future, and the company is so far succeeding in diagnostics while medical device sales falter.

Abbott CEO scores $25M, while new AbbVie chief nets $8M

Abbott Laboratories gives us a two-fer in the proxy department. It filed its own annual-meeting documents, and so did its newly birthed spinoff AbbVie. Not surprisingly, Abbott Chairman and CEO Miles White once again collected more than $25 million in compensation for the year.

Abbott's CEO paycheck bigger than its tax bill, study says

Some companies pay their CEOs more than they pay in U.S. taxes. That's the somewhat sensational conclusion of a study from the Institute for Policy Studies, a Washington, D.C. think tank. And among them, the IPS says, is Abbott Laboratories' CEO Miles White, a perennial top earner among Big Pharma executives.

Abbott opens the books on pharma spinoff

Pharma breakup followers, take note: Abbott Laboratories ($ABT) has unveiled its first-draft documents for the AbbVie spinoff. In a letter to shareholders filed with the Securities and Exchange Commission, Abbott discloses its management team, sets forth pro forma financials, and runs down the trends on product sales.

How does pharma's CEO pay rank?

We know how pharma CEO pay stacked up within the industry. But how did pharma's 2011 compensation packages compare with those in other industries?

Abbott touts positive Parkinson's Phase III as pharma split looms

Banking on double-digit earnings growth and a string of pipeline deals and developments, Abbott Laboratories execs said they are "on track" to go ahead and spin off the pharma side of the business later this year.

Abbott's White saw compensation drop in 2011

Abbott Laboratories ($ABT) had a memorable 2011 capped off by announcing that it would split into two companies: a pharma business and a medical products company. CEO Miles White (pictured), who will continue to lead the diversified medical products company, saw his total compensation fall slightly in 2011, coming in at just above $24 million. That's down about 6% from $25.6 million a year earlier.

Abbott's White sees bonus, stock awards slip

Abbott Laboratories Chairman and CEO Miles White (photo) received a 2 percent raise last year, to $1.89 million. However, his bonus and other stock awards dipped, according to an SEC filing. White